Semaglutide's heart benefits explored in new study

NCT ID NCT07190144

Completed Knowledge-focused Sponsor: Ekrem Bilal Karaayvaz Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed observational study examined whether semaglutide, a drug used for diabetes and weight loss, improves blood flow in the coronary arteries. Researchers measured coronary flow reserve in 122 diabetic and non-diabetic patients before and after 3 months of treatment. The study aimed to see if the drug enhances heart vessel function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this could show that semaglutide improves blood flow to the heart, pointing toward a new benefit of the drug beyond diabetes and weight loss.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also completed, so no new data is being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY &AMP; OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY &AMP; OVERWEIGHT THE STUDY FOCUSED ON THE VASCULAR EFFECTS OF SEMAGLUTIDE IN BOTH DIABETIC AND NON-DIABETIC PATIENTS

Semaglutide's heart benefits explored in new study

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions